Magrax-F 120mg Davipharm treatment for acute gout (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Etoricoxib

Ingredient

Composition information	Content
Etoricoxib	120mg

Uses

indications

Magrax-F medicine is indicated in the following cases:

Treatment of acute gout.

The drug is used to reduce symptoms of rheumatoid arthritis, osteoarthritis and acute gout.

pharmacokinetics

absorption: Etoricoxib is well absorbed by oral. Absolute bioavailability is approximately 100%. After taking 120 mg 1 time/day to the status of constant, the peak concentration of plasma (cmax = 3.6 µg/ml) is achieved after 1 hour. The area under the curve is 37.8 µg. HR/mL. Mobile pharmacokinetics of linear Etoricoxib in the treatment dose range. Food does not affect Etoricoxib's absorption but affects the absorption rate.

Distribution: about 92% Etoricoxib attaches plasma proteins in the concentration of 0.05–5 µg/ml. The integral distribution is about 120 l.

Metabolism: The drug is large metabolized with

Determined 5 metabolites in humans. The metabolite is the 6 'carboxylic acid of etoricoxib acid formed mainly by oxidation of the 6' hydroxymethyl substance. The metabolites are mainly inactive or have weak COX-2 inhibitors. No metabolites inhibit COX-1.

Elimination: After an intravenous injection of a single dose of 25 mg Etoricoxib marks radioactive marks in healthy people, 70% of radioactive activity is found in urine and 20% in feces, mainly in the form of metabolites. Under 2% is found in a constant form.

Etoricoxib elimination is mainly in the form of metabolites by the excretion of the kidneys. Etoricoxib's constant concentration is achieved within 7 days after taking 120 mg once a day, half a lifetime is about 22 hours. Plasma clearance after 1 dose of 25 mg intravenously estimates about 50 ml/ min.

Before taking Magrax-F 120mg Davipharm treatment for acute gout (3 blisters x 10 tablets)

How to use

Magrax-F medicine for oral use.

Dosage

Dosage for treatment of Gout Gout: 120 mg/day. The dose of 120 mg is only used in the stage and is not used more than 8 days.

Dosage for patients with liver failure: Maximum oral dose in mild liver failure patients (Child-Pugh: 5–6 points) is 60 mg, 1 time/day. Patients with average liver failure (Child-Pugh: 7–9 points) is 60 mg every 2 days or 30 mg/day. Etoricoxib should not be used in patients with severe liver failure (Child-Pugh: ≥ 10 points).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

In clinical studies, the single dose is only 500 mg and the repeated dose of 150 mg/day for 21 days without signs of toxicity.

In case of overdose, normal treatment should be taken such as removing not absorbed from the gastrointestinal tract, clinical monitoring and supportive treatment if necessary. Hematopalysts cannot eliminate Etoricoxib. It is not clear the effectiveness of removing the body from the peritoneal fertilizer.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Magrax-F, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Metabolism and nutrition: edema, fluid.

nerve: dizziness, headache. circuit: Hypertension. digestive: Disorders of the digestive system (abdominal pain, flatulence, heartburn), diarrhea, indigestion, epigastric pain, nausea. Systemic: weakness, influenza.

Testing: Increase ALT, AST.

Uncommon, 1/1000

Infections: gastritis - intestines, upper respiratory infections, urinary tract infections.

Metabolism and nutrition: Increase or decrease appetite, weight gain.

Mental: Anxiety, depression.

Neurological: Disorder, insomnia, Perfect, Sleeping.

senses: blurred vision, tinnitus.

Cardiovascular: congestive heart failure, Non -specific ECG changes, myocardial infarction.

circuit: flushed, stroke.

Respiratory: cough, shortness of breath, nosebleeds.

Digestive: Acid reflux, changes in bowel movements, constipation, dry mouth, stomach ulcers - colon, irritable bowel syndrome, esophagitis, mouth ulcers, vomiting.

Skin and subcutaneous tissue: bruising, facial edema, itching, rash.

Muscle, connective tissue and bone: cramps, muscle pain, muscle hardness.

Urinary system: proteinuria.

Testing: hyperuremia, increased creatine phosphokinase, hematocrit decrease, hemoglobin decrease, hyperkalemia, platelet decrease, serum creatinine, hyperkemia.

other ADR: chest pain.

Very rare, ADR

Immune: Hypersensitivity reactions, including angels, anaphylactic reactions.

Mental: confused, hallucinations.

Hypertension.

Respiratory: Bronchospasm.

digestive: Gastrointestinal ulcer includes perforation and stomach bleeding (mainly in the elderly).

Hepatitis: Hepatitis.

Skin and subcutaneous tissue: urticaria, Stevens - Johnson syndrome, poisoned epidermal necrosis.

urinary tract: renal failure, often recovered after stopping the drug.

Instructions on how to handle ADR

Notify the doctor the unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Magrax-F drug contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Stomach ulcers or gastrointestinal bleeding.

Severe renal failure (CLCR

History of asthma, acute rhinitis, nasal polyps, neurotransmitters, urticaria when taking aspirin or nsaids.

Pregnant or lactating women.

Children under 16 years old.

cystitis.

Mild to severe liver failure. heart failure.

Inflammation.

Be cautious when used

Caution in patients with anemia heart disease, kidney failure, cirrhosis, left ventricular dysfunction, hypertension, risk of edema, older people, patients dehydration, hyperlipidemia, diabetes.

When using high doses of 120 mg/day, do not use more than 8 days.

Risk of cardiovascular thrombosis: NSAIDs, not aspirin, using systemic sugar can increase the risk of cardiovascular thrombosis, including myocardial infarction and stroke, which can lead to death. This risk can appear early in the first few weeks of taking the drug and can increase over time.

The risk of cardiovascular thrombosis is mainly at high doses. Doctors need to periodically assess the appearance of cardiovascular events, even if the patient has no previous cardiovascular symptoms. Patients should be warned of symptoms of serious cardiovascular events and need to visit the doctor as soon as they appear.

To minimize the risk of adverse events, Etoricoxib is needed at the lowest daily daily doses in the shortest possible time.

The ability to drive and operate machinery

No information.

Pregnancy

Like other drugs that inhibit the synthesis of prostaglandin, it is necessary to avoid using Etoricoxib in late pregnant women because it can cause early arterioscler. There are no adequate control studies on pregnant women. Etoricoxib should only be used in the first two quarters of pregnancy if the benefit it brings is greater than the risk to the fetus.

Breastfeeding period

Etoricoxib is excreted in mouse milk. It is not known whether it is excreted in breast milk or not. Because there are many drugs excreted in breast milk and because of the possible effects of prostaglandin synthesis inhibitors during the breastfeeding period, the decision to stop the drug or stop breastfeeding depends on the importance of the drug for the mother.

Drug interaction

Warfarin

In patients with stable treatment with warfarin, using the daily dosage of Etoricoxib 120 mg can lead to an increase of about 13% of prothrombin compared to international standard ratio (INR). It is necessary to strictly control the INR value when starting with Etoricoxib or when transferred to Etoricoxib treatment, especially on the first days, when the patient is using Warfarin or the same substance.

rifampin

Simultaneous use of Etoricoxib with rifampin, a agent capable of causing metabolic enzyme induction in strong liver, reducing 65% of the area under the curve (AUC) in the plasma of Etoricoxib. This interaction should be taken into account when Etoricoxib is used with rifampin.

methotrexate

Need to monitor the toxicity of methotrexate when using Etoricoxib simultaneously with a dose greater than 90 mg daily and methotrexate.

Angiotensin (ACE) transferring inhibitors: There have been reports that acknowledges that the COX inhibitors are not selective and selective inhibition of COX-2 can reduce the anti-hypertension effect of ACE inhibitors.

lithium

There has been a report that acknowledges that COX inhibitors are not selective and selective inhibition of COX-2 may increase plasma lithium levels.

aspirin

Low -doseed simultaneous use with Etoricoxib can lead to an increase in gastrointestinal ulcer and other complications compared to the case of Etoricoxib only.

contraceptive drugs: Etoricoxib treated with a dose of 120 mg with a birth control pills containing 35 mcg ethinyl estradiol (EE) and 0.5–1 mg norethindrone in 21 days, simultaneous use or 12 hours apart, increasing the AUC in the stable state of EE to 50–60%.

Storage

Store in a dry place, avoid light, temperature not exceeding 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.